Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6da69a4f66c24b72439544c96ca4f977> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6da69a4f66c24b72439544c96ca4f977 NCIT_P378 "NCI" @default.
- B6da69a4f66c24b72439544c96ca4f977 type Axiom @default.
- B6da69a4f66c24b72439544c96ca4f977 annotatedProperty IAO_0000115 @default.
- B6da69a4f66c24b72439544c96ca4f977 annotatedSource NCIT_C137825 @default.
- B6da69a4f66c24b72439544c96ca4f977 annotatedTarget "The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG." @default.